Overexpression of miR-613 enhanced radiosensitivity of colorectal cancer cells via targeting downregulation of Wee1

doi:10.3760/cma.j.issn.1673-422X.2019.03.006

Abstract

Abstract: ObjectiveTo explore the effect of microRNA613 (miR613)/Wee1 axis on the radiosensitivity of colorectal cancer cells. MethodsA total of 20 patients with radiosensitive colorectal cancer and 20 patients with radioresistance were selected from Yan′an Hospital Affiliated to Kunming Medical University from November 2016 to May 2017. Human colorectal cancer cell lines LoVo and HCT116 were selected and the radioresistant cell lines LoVo/R and HCT116/R were established for subsequent experiments. Realtime fluorescence quantitative PCR (qRTPCR) was used to detect the expression of miR613 and Wee1 in colorectal cancer tissues and cell lines. The radioresistant cells were transfected by miR613 mimic, and nontransfected cells were used as control group. The effects of miR613 overexpression on the proliferation, invasion and cell cycle of radiation resistance of colorectal cancer cells at different radiation doses were evaluated by CCK8 assay, Transwell assay and Western blotting, respectively. Furthermore, dualluciferase reporter gene assay was used to verify whether Wee1 was a target gene of miR613. siWee1 was transfected into radioresistant cells of colorectal cancer, or cotransfected with siWee1 and miR613 inhibitor, and nontransfected cells were used as control group. The effects of miR613/Wee1 axis on cell proliferation, invasion and cell cycle were detected by CCK8, Transwell and Western blotting at different radiation doses. ResultsThe expression of miR613 was downregulated in the radiation resistance group of patients (1.54±0.25 vs. 2.64±0.45; t=3.140，P=0.009) and radiation resistance cell lines (LoVo/R vs. LoVo: 1.03±0.12 vs. 3.05±0.15; t=8.944, P=0.006; HCT116/R vs. HCT116: 1.01±0.11 vs. 2.85±0.16; t=8.050, P=0.008). Overexpression of miR613 was significantly inhibited the proliferation (LoVo/R: t6 Gy=6.018, P=0.013; HCT116/R: t6 Gy=5.634, P=0.015) and invasion (LoVo/R: 45.00±8.95 vs. 180.15±6.95, t6 Gy=11.93, P=0.003; HCT116/R: 49.97±6.21 vs. 170.20±7.03, t6 Gy=12.82, P=0.006) of LoVo/R and HCT116/R cells and decreased the expression levels of G2M phase cell cycle correlated proteins (CDK1 and cyclin B). Moreover, dualluciferase reporter gene assay confirmed that Wee1 was a target of miR613. Mechanistically, overexpression of miR613 promoted the radiosensitivity of LoVo/R and HCT116/R cells through inhibiting cell proliferation (compared with siWee1 group, cotransfected with siWee1 and miR613 inhibitor, and control group, LoVo/R: F8 Gy=40.742, P=0.007; HCT116/R: F8 Gy=28.958, P=0.011), invasion (LoVo/R: F8 Gy=55.413, P=0.004; HCT116/R: F8 Gy=65.634, P=0.003) and arresting cell at G2M phase via downregulating Wee1. ConclusionmiR613/Wee1 axis plays a certain role in regulating the radiation resistance of colorectal cancer cells, overexpression of miR613 may reverse the radiation resistance of colorectal cancer cells.

Key words: MicroRNAs, Colorectal neoplasms, Wee1, Radiosensitivity

Zhao Weishan, Zhu Yankun, Wang Ruotian, Guan Aoran, Li Ruhong. Overexpression of miR-613 enhanced radiosensitivity of colorectal cancer cells via targeting downregulation of Wee1[J]. Journal of International Oncology, 2019, 46(3): 157-165.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. DOI: 10.3322/caac.20107. ［2］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87108. DOI: 10.3322/caac.21262. ［3］ Li B, Xie Z, Li Z, et al. MicroRNA613 targets FMNL2 and suppresses progression of colorectal cancer［J］. Am J Transl Res, 2016, 8(12): 54755484. ［4］ Guan S, Wang C, Chen X, et al. MiR613: a novel diagnostic and prognostic biomarker for patients with esophageal squamous cell carcinoma［J］. Tumour Biol, 2016, 37(4): 43834391. DOI: 10.1007/s1327701542718. ［5］ Fu X, Cui Y, Yang S, et al. MicroRNA613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS［J］. Tumour Biol, 2016, 37(5): 64776483. DOI: 10.1007/s1327701545077. ［6］ Chen X, Xu Y, Liao X, et al. Plasma miRNAs in predicting radiosensitivity in nonsmall cell lung cancer［J］. Tumour Biol, 2016, 37(9): 1192711936. DOI:10.1007/s1327701650528. ［7］ Zhang J, Zhang Y, Li X, et al. MicroRNA212 inhibits colorectal cancer cell viability and invasion by directly targeting PIK3R3［J］. Mol Med Rep, 2017, 16(5): 78647872. DOI: 10.3892/mmr.2017.7552. ［8］ Andaur R, Tapia JC, Moreno J, et al. Differential miRNA expression profiling reveals miR2053p to be a potential radiosensitizer for low dose ionizing radiation in DLD1 cells［J］. Oncotarget, 2018, 9(41): 2638726405. DOI: 10.18632/oncotarget.25405. ［9］ Ruhl R, Rana S, Kelley K, et al. microRNA451a regulates colorectal cancer proliferation in response to radiation［J］. BMC Cancer, 2018, 18(1): 517. DOI: 10.1186/s1288501843701. ［10］ Hu JL, He GY, Lan XL, et al. Inhibition of ATG12mediated autophagy by miR214 enhances radiosensitivity in colorectal cancer［J］. Oncogenesis, 2018, 7(2): 16. DOI: 10.1038/s4138901800288. ［11］ Yang P, Yang Y, An W, et al. The long noncoding RNAROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR145 pathway［J］. J Gastroenterol Hepatol, 2017, 32(4): 837845. DOI:10.1111/jgh.13606. ［12］ Zheng L, Zhang Y, Liu Y, et al. MiR106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer［J］. J Transl Med, 2015, 13: 252. DOI: 10.1186/s129670150592z. ［13］ Liu KC, Shih TY, Kuo CL, et al. Sulforaphane induces cell death through G2/M phase arrest and triggers apoptosis in HCT 116 human colon cancer cells［J］. Am J Chin Med, 2016, 44(6): 12891310. DOI: 10.1142/S0192415X16500725. ［14］ Ge XC, Wu F, Li WT, et al. Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer［J］. Oncol Lett, 2017, 13(6): 43414348. DOI: 10.3892/ol.2017.5984. ［15］ Webster PJ, Littlejohns AT, Gaunt HJ, et al. Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases［J］. Oncotarget, 2017, 8(26): 4228842299. DOI: 10.18632/oncotarget.15039. ［16］ Liu YL, Zhang GQ, Yang Y, et al. Genistein induces G2/M arrest in gastric cancer cells by increasing the tumor suppressor PTEN expression［J］. Nutr Cancer, 2013, 65(7): 10341041. DOI: 10.1080/01635581.2013.810290. ［17］ Friedman J, Morisada M, Sun L, et al. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies［J］. J Immunother Cancer, 2018, 6(1): 59. DOI: 10.1186/s4042501803742. ［18］ Zhang LL, Feng ZL, Su MX, et al. Downregulation of Cyclin B1 mediates nagilactone Einduced G2 phase cell cycle arrest in nonsmall cell lung cancer cells［J］. Eur J Pharmacol, 2018, 830: 1725. DOI: 10.1016/j.ejphar.2018.04.020. ［19］ Brockway S, ZeleznikLe NJ. WEE1 is a validated target of the microRNA miR1792 cluster in leukemia［J］. Cancer Genet, 2015, 208(5): 279287. DOI: 10.1016/j.cancergen.2015.01.001. ［20］ Chen B, Duan L, Yin G, et al. miR381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5FU by upregulation of Cdc2 activities in 786O［J］. J Chemother, 2013, 25(4): 229238. DOI: 10.1179/1973947813Y.0000000092. ［21］ Creevey L, Ryan J, Harvey H, et al. MicroRNA497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1［J］. Mol Cancer, 2013, 12: 23. DOI: 10.1186/147645981223.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[7]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[8]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[9]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[10]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[11]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[12]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[13]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[14]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[15]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.